Related Experiment Video
Updated: Jan 31, 2026

Preparation and Analysis of In Vitro Three Dimensional Breast Carcinoma Surrogates
Published on: May 9, 2016
AR-Variant-Positive CTC: A Surrogate for a Surrogate for Taxane Therapy Outcome?
Scott M Dehm1, Bruce Montgomery2,3, Stephen R Plymate4,3
1Masonic Cancer Center, Department of Laboratory Medicine and Pathology, Department of Urology, University of Minnesota, Minneapolis, Minnesota.
Abstract:
Circulating tumor cells' (CTC) biomarkers may become indicators for selection of therapy. The presence of androgen receptor (AR)-variant-positive CTCs may be markers indicating the need for switching therapy. Methods for AR-variant mRNA isolation from CTCs and confirmation of expression are critical factors needed for these techniques to be clinically applicable.See related article by Tagawa et al., p. 1880.
Related Concept Videos
Histone Variants at the Centromere
Predicting Reaction Outcomes
Outcomes of Glycolysis
Cellular respiration can occur aerobically (with oxygen) or anaerobically (without oxygen). In the presence of oxygen, cellular respiration starts with glycolysis and continues with pyruvate...
Position-effect Variegation
Guidelines for Writing Outcome
Patient outcomes reflect the patient's response to the goal rather than what the nurse aims to achieve. Terminology should be observable and measurable to avoid the reader's interpretation. The desired outcome should be realistic and achievable in the designated care timeframe. Expected outcomes should align with adjunctive therapies. The outcome should enhance care...
Gene Therapy

